The invention relates to a pharmaceutical formulation with delayed release of the agent, containing 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or one of the pharmaceutically acceptable salts thereof in a matrix. Said matrix contains 1 to 80 percent by weight of one or several hydrophilic or hydrophobic polymer/s as pharmaceutically acceptable matrix-forming substance/s and has the following dissolution rate: 3-35 percent by weight (relative to 100 percent by weight of active substance) of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 0.5 hours； 5-50 percent by weight of % 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 1 hour； 10-75 percent by weight of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 2 hours； 15-82 percent by weight of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 3 hours； 30-97 percent by weight of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 6 hours； more than 50 percent by weight of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 12 hours； more than 70 percent by weight of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 18 hours； more than 80 percent by weight of 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol are released after 24 hours.
